PIK3CA and colorectal carcinoma: The exact definition of the molecular mechanisms underlying such crosstalk deserves further investigation and may provide clues to the selection of CRC patients at the highest chance to benefit from PI3K pathway inhibitors and provide the rationale for novel therapeutic approaches.